Apimeds Pharmaceuticals US, Inc. SEC filings APUS
Apimeds Pharmaceuticals US, Inc. has 130 filings in SEC EDGAR's recent list, going back to Jan 29, 2024. Its latest annual report, Form 10-K, was filed on May 4, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 13, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 3 | Initial insider ownership | Nov 5, 2026 | Oct 1, 2026 |
| 3 | Initial insider ownership | Nov 2, 2026 | Dec 1, 2025 |
| 3 | Initial insider ownership | Nov 2, 2026 | Dec 1, 2025 |
| 8-K |
Current report
Other events
|
Oct 13, 2026 | Oct 4, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 1, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Other events
|
Sep 29, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Sep 23, 2026 | Jul 24, 2026 |
| 8-K |
Current report
Material agreement, Officer or director change
|
Sep 11, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Material agreement
|
Aug 21, 2026 | Aug 19, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Aug 6, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Other events
|
Jul 13, 2026 | Jul 13, 2026 |
| 10-Q | Quarterly report | May 26, 2026 | Mar 31, 2026 |
| NT 10-Q | Notification of late filing | May 15, 2026 | Mar 31, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | May 7, 2026 | — |
| 8-K |
Current report
Officer or director change
|
May 5, 2026 | May 5, 2026 |
| 10-K | Annual report | May 4, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Material agreement, Officer or director change, Other events
|
May 4, 2026 | Apr 24, 2026 |
| 8-K |
Current report
Listing notice
|
Apr 22, 2026 | Apr 17, 2026 |
| 8-K |
Current report
Other events
|
Apr 16, 2026 | Apr 15, 2026 |
| 425 | Amendment no. 1 to form 8-k | Apr 9, 2026 | — |
| 8-K/A |
Amended current report
Officer or director change, Bylaw or fiscal year change, Other events
|
Apr 9, 2026 | Mar 20, 2026 |
| NT 10-K | Notification of late filing | Mar 31, 2026 | Dec 31, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Mar 30, 2026 | — |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Other events
|
Mar 26, 2026 | Mar 20, 2026 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Other events
|
Mar 25, 2026 | Mar 20, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Mar 20, 2026 | — |
| 8-K |
Current report
Other events
|
Mar 16, 2026 | Mar 16, 2026 |
| DEFM14C | Information statement | Feb 27, 2026 | — |
| 425 | Amendment no. 2 to form 8-k | Feb 17, 2026 | — |
| 8-K/A |
Amended current report
Acquisition or sale of assets
|
Feb 17, 2026 | Dec 1, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 11, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jan 26, 2026 | — |
| PREM14C | Information statement | Jan 16, 2026 | Jan 16, 2026 |
| 8-K |
Current report
Officer or director change
|
Jan 2, 2026 | Dec 30, 2025 |
| 8-K |
Current report
Officer or director change
|
Dec 10, 2025 | Dec 5, 2025 |
| 8-K/A |
Amended current report
Material agreement, Change to shareholder rights, Bylaw or fiscal year change
|
Dec 10, 2025 | Dec 1, 2025 |
| 425 | Current report | Dec 2, 2025 | — |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, New debt, Unregistered share sale, Change in control, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
|
Dec 2, 2025 | Dec 1, 2025 |
| 4/A | Primary document | Nov 21, 2025 | May 12, 2024 |
| 8-K |
Current report
Officer or director change
|
Nov 18, 2025 | Nov 13, 2025 |
| 4 | Insider transaction | Nov 13, 2025 | Nov 11, 2025 |
| 4 | Insider transaction | Nov 13, 2025 | Nov 11, 2025 |
| 4 | Insider transaction | Nov 13, 2025 | Nov 11, 2025 |
| 4 | Insider transaction | Nov 13, 2025 | Nov 11, 2025 |
| 4 | Insider transaction | Nov 13, 2025 | Nov 11, 2025 |
| 10-Q | Quarterly report | Nov 12, 2025 | Sep 30, 2025 |
| 4 | Insider transaction | Oct 24, 2025 | Oct 15, 2025 |
| 4 | Insider transaction | Oct 21, 2025 | Oct 15, 2025 |
| 4 | Insider transaction | Oct 17, 2025 | Oct 15, 2025 |
| 4 | Insider transaction | Oct 17, 2025 | Oct 15, 2025 |
| 4 | Insider transaction | Oct 17, 2025 | Oct 15, 2025 |
| 4 | Insider transaction | Oct 17, 2025 | Oct 15, 2025 |
| 4 | Insider transaction | Oct 17, 2025 | Oct 15, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Oct 16, 2025 | Oct 15, 2025 |
| 10-Q | Quarterly report | Aug 19, 2025 | Jun 30, 2025 |
| NT 10-Q | Notification of late filing | Aug 14, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 16, 2025 | Jul 15, 2025 |
| 4/A | Primary document | Jun 11, 2025 | May 12, 2025 |
| 3/A | Primary document | Jun 11, 2025 | Mar 4, 2025 |
| 8-K |
Current report
Officer or director change
|
Jun 5, 2025 | May 30, 2025 |
| S-8 | Employee stock plan registration | May 23, 2025 | — |
| 4 | Insider transaction | May 20, 2025 | May 16, 2025 |
| 4 | Insider transaction | May 20, 2025 | May 16, 2025 |
| 4 | Insider transaction | May 20, 2025 | May 16, 2025 |
| 4 | Insider transaction | May 20, 2025 | May 16, 2025 |
| 4 | Insider transaction | May 20, 2025 | May 16, 2025 |
| 4 | Insider transaction | May 20, 2025 | May 16, 2025 |
| 4 | Insider transaction | May 20, 2025 | May 16, 2025 |
| 8-K |
Current report
Material agreement
|
May 20, 2025 | May 16, 2025 |
| 10-Q | Quarterly report | May 20, 2025 | Mar 31, 2025 |
| SCHEDULE 13D | Ownership over 5% (active) | May 19, 2025 | — |
| 4 | Insider transaction | May 15, 2025 | May 13, 2025 |
| NT 10-Q | Notification of late filing | May 15, 2025 | Mar 31, 2025 |
| 4 | Insider transaction | May 14, 2025 | May 12, 2025 |
| 4 | Insider transaction | May 14, 2025 | May 12, 2025 |
| 3/A | Primary document | May 14, 2025 | Mar 4, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
May 12, 2025 | May 8, 2025 |
| 424B4 | Prospectus | May 9, 2025 | — |
| 3 | Initial insider ownership | May 8, 2025 | Mar 4, 2025 |
| 3 | Initial insider ownership | May 8, 2025 | Mar 4, 2025 |
| 3 | Initial insider ownership | May 8, 2025 | Mar 4, 2025 |
| 3 | Initial insider ownership | May 8, 2025 | Mar 4, 2025 |
| 3 | Initial insider ownership | May 8, 2025 | Mar 4, 2025 |
| 3 | Initial insider ownership | May 8, 2025 | Mar 4, 2025 |
| 3 | Initial insider ownership | May 8, 2025 | Mar 4, 2025 |
| 3 | Initial insider ownership | May 8, 2025 | Mar 4, 2025 |
| 3 | Initial insider ownership | May 8, 2025 | Mar 4, 2025 |
| EFFECT | Filing | May 5, 2025 | — |
| CORRESP | Letter to the SEC | May 5, 2025 | — |
| CORRESP | Letter to the SEC | May 5, 2025 | — |
| UPLOAD | Letter from the SEC | May 5, 2025 | — |
| POS AM | Post-effective amendment | May 2, 2025 | — |
| 10-K/A | Amended annual report | May 2, 2025 | Dec 31, 2024 |
| CORRESP | Letter to the SEC | May 1, 2025 | — |
| CORRESP | Letter to the SEC | May 1, 2025 | — |
| POS AM | Post-effective amendment | May 1, 2025 | — |
| UPLOAD | Letter from the SEC | May 1, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 30, 2025 | — |
| POS AM | Post-effective amendment | Apr 17, 2025 | — |
| 10-K | Annual report | Apr 15, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Apr 15, 2025 | Apr 11, 2025 |
| NT 10-K | Notification of late filing | Mar 31, 2025 | Dec 31, 2024 |
| CERT | Nyse american certification | Mar 4, 2025 | — |
| 8-A12B | For registration of certain classes | Mar 3, 2025 | — |
| EFFECT | Filing | Feb 11, 2025 | — |
| FWP | Free writing prospectus | Feb 10, 2025 | — |
| CORRESP | Letter to the SEC | Feb 10, 2025 | — |
| S-1/A | Amended registration statement | Feb 10, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 7, 2025 | — |
| CORRESP | Letter to the SEC | Feb 7, 2025 | — |
| CORRESP | Letter to the SEC | Feb 7, 2025 | — |
| S-1/A | Amended registration statement | Feb 6, 2025 | — |
| S-1/A | Amended registration statement | Jan 29, 2025 | — |
| S-1/A | Amended registration statement | Jan 10, 2025 | — |
| S-1/A | Amended registration statement | Dec 20, 2024 | — |
| CORRESP | Letter to the SEC | Dec 19, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 16, 2024 | — |
| S-1/A | Amended registration statement | Dec 9, 2024 | — |
| S-1/A | Amended registration statement | Nov 8, 2024 | — |
| S-1 | Registration statement | Sep 25, 2024 | — |
| DRS/A | Filing | Aug 5, 2024 | — |
| DRSLTR | Filing | Aug 2, 2024 | — |
| DRS/A | Filing | Jun 17, 2024 | — |
| DRSLTR | Filing | Jun 14, 2024 | — |
| UPLOAD | Letter from the SEC | May 23, 2024 | — |
| DRSLTR | Filing | May 13, 2024 | — |
| DRS/A | Filing | May 13, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 26, 2024 | — |
| DRS | Filing | Jan 29, 2024 | — |
Showing 130 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- APUS (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Matawan, NJ
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1894525
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.